Effects of continuous positive airway pressure on coagulability in obstructive sleep apnoea: A randomised, placebo-controlled crossover study

Thorax

Volumn 67, Issue 7, 2012, Pages 639-644

  Phillips, Craig L ^a,b   McEwen, Bradley J ^a,c   Morel Kopp, Marie Christine ^a,c   Yee, Brendon J ^b,d   Sullivan, David R ^d   Ward, Christopher M ^a,c   Tofler, Geoffrey H ^a   Grunstein, Ronald R ^b,d  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; D DIMER; FIBRINOGEN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; VON WILLEBRAND FACTOR;

ADULT; APNEA HYPOPNEA INDEX; ARTICLE; BLOOD ANALYSIS; BLOOD CLOTTING; CARDIOVASCULAR RISK; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; FEMALE; HUMAN; MALE; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SLEEP APNEA SYNDROME; SLEEP WAKING CYCLE; THROMBOSIS; TREATMENT OUTCOME;

EID: 84862759417     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2011-200874     Document Type: Article

References (49)

1. Marshall NS, Wong KK, Liu PY, et al. Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study. Sleep 2008;31:1079-85.
2. Young T, Finn L, Peppard P, et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep 2008;31:1071-8.
3. Redline S, Yenokyan G, Gottlieb DJ, et al. Obstructive sleep apnea hypopnea and incident stroke: the Sleep Heart Health Study. Am J Respir Crit Care Med 2010;182:269-77.
4. Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the Sleep Heart Health Study. Circulation 2010;122:352-60.
5. Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005;365:1046-53.
6. Bazzano LA, Khan Z, Reynolds K, et al. Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. Hypertension 2007;50:417-23.
7. Cross MD, Mills NL, Al-abri M, et al. Continuous positive airway pressure improves vascular function in obstructive sleep apnea hypopnea syndrome: a randomized controlled trial. Thorax 2008;63:578-83.
8. Jelic S, Padeletti M, Kawut SM, et al. Inflammation, oxidative stress, and repair capacity of the vascular endothelium in obstructive sleep apnea. Circulation 2008;117:2270-8.
9. von Känel R, Loredo JS, Ancoli-Israel S, et al. Association between polysomnographic measures of disrupted sleep and prothrombotic factors. Chest 2007;131:733-9.
10. von Kanel R, Natarajan L, Ancoli-Israel S, et al. Day/night rhythm of hemostatic factors in obstructive sleep apnea. Sleep 2010;33:371-7.
11. Terada S, Koyama T, Watanabe H, et al. Abnormal coagulation and platelet profile in patients with obstructive sleep apnea syndrome. Int J Cardiol 2011;146:423-5.
12. Zamarrón C, Ricoy J, Riveiro A, et al. Plasminogen activator inhibitor-1 in obstructive sleep apnea patients with and without hypertension. Lung 2008;186:151-6.
13. Mehra R, Xu F, Babineau DC, et al. Sleep disordered breathing and pro-thrombotic biomarkers: cross-sectional results of the Cleveland Family Study. Am J Respir Crit Care Med 2010;182:826-33.
14. von Känel R, Loredo J, Ancoli-Israel S, et al. Association between sleep apnea severity and blood coagulability: treatment effects of nasal continuous positive airway pressure. Sleep Breath 2006;10:139-46.
15. Guardiola JJ, Matheson PJ, Clavijo LC, et al. Hypercoagulability in patients with obstructive sleep apnea. Sleep Med 2001;2:517-23.
16. Robinson GV, Pepperell JC, Segal HC, et al. Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials. Thorax 2004;59:777-82.
17. Haus E. Chronobiology of hemostasis and inferences for the chronotherapy of coagulation disorders and thrombosis prevention. Adv Drug Deliv Rev 2007;59:966-84.
18. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989;79:733-43.
19. Goldberg RJ, Brady P, Muller JE, et al. Time of onset of symptoms of acute myocardial infarction. Am J Cardiol 1990;66:140-4.
20. Gami AS, Howard DE, Olson EJ, et al. Dayenight pattern of sudden death in obstructive sleep apnea. N Engl J Med 2005;352:1206-14.
21. Willich SN, Levy D, Rocco MB, et al. Circadian variation in the incidence of sudden cardiac death in the Framingham Heart Study population. Am J Cardiol 1987;60:801-6.
22. Sert-Kuniyoshi FH, Garcia-Touchard A, Gami AS, et al. Dayenight variation of acute myocardial infarction in obstructive sleep apnea. J Am Coll Cardiol 2008;52:343-6.
23. Bokinsky G, Miller M, Ault K, et al. Spontaneous platelet activation and aggregation during obstructive sleep apnea and its response to therapy with nasal continuous positive airway pressure. Chest 1995;108:625-30.
24. Phillips CL, Yee BJ, Marshall NS, et al. Continuous positive airway pressure reduces postprandial lipidemia in obstructive sleep apnea: a randomised, placebo controlled crossover trial. Am J Respir Crit Care Med 2011;184:355-61.
25. Anon. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force [see comment]. Sleep 1999;22:667-89.
26. El Solh A, Akinnusi M, Berim I, et al. Hemostatic implications of endothelial cell apoptosis in obstructive sleep apnea. Sleep Breath 2008;12:331-7.
27. Chin K, Kita H, Noguchi T, et al. Improvement of factor VII clotting activity following long-term NCPAP treatment in obstructive sleep apnoea syndrome. QJM 1998;91:627-33.
28. Chin K, Ohi M, Kita H, et al. Effects of NCPAP therapy on fibrinogen levels in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 1996;153:1972-6.
29. Rangemark C, Hedner JA, Carlson JT, et al. Platelet function and fibrinolytic activity in hypertensive and normotensive sleep apnea patients. Sleep 1995;18:188-94.
30. Sanner BM, Konermann M, Tepel M, et al. Platelet function in patients with obstructive sleep apnoea syndrome. Eur Respir J 2000;16:648-52.
31. von Kanel R, Le DT, Nelesen RA, et al. The hypercoagulable state in sleep apnea is related to comorbid hypertension. J Hypertens 2001;19:1445-51.
32. Zamarrón-Sanz C, Ricoy-Galbaldon J, Gude-Sampedro F, et al. Plasma levels of vascular endothelial markers in obstructive sleep apnea. Arch Med Res 2006;37:552-5.
33. Peled N, Kassirer M, Kramer MR, et al. Increased erythrocyte adhesiveness and aggregation in obstructive sleep apnea syndrome. Thromb Res 2008;121:631-6.
34. Wessendorf TE, Thilmann AF, Wang YM, et al. Fibrinogen levels and obstructive sleep apnea in ischemic stroke. Am J Respir Crit Care Med 2000;162:2039-42.
35. Dorkova Z, Petrasova D, Molcanyiova A, et al. Effects of continuous positive airway pressure on cardiovascular risk profile in patients with severe obstructive sleep apnea and metabolic syndrome. Chest 2008;134:686-92.
36. Shitrit D, Peled N, Shitrit AB, et al. An association between oxygen desaturation and D-dimer in patients with obstructive sleep apnea syndrome. Thromb Haemost 2005;94:544-7.
37. Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011;364:1746-60.
38. Meade TW, Brozovic M, Chakrabarti RR, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986;328:533-7.
39. Meade TW, North WR, Chakrabarti R, et al. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980;1:1050-4.
40. Kraaijenhagen RA, in't Anker PS, Koopman MM, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000;83:5-9.
41. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991;66:351-5.
42. Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation 2008;117:1449-59.
43. Redondo M, Watzke HH, Stucki B, et al. Coagulation factors II, V, VII, and X, prothrombin gene 20210G/A transition, and factor V Leiden in coronary artery disease: high factor V clotting activity is an independent risk factor for myocardial infarction. Arterioscler Thromb Vasc Biol 1999;19:1020-5.
44. Konecny T, Sert Kuniyoshi FH, Orban M, et al. Under-diagnosis of sleep apnea in patients after acute myocardial infarction. J Am Coll Cardiol 2010;56:742-3.
45. Epstein MD, Segal LN, Ibrahim SM, et al. Snoring and the risk of obstructive sleep apnea in patients with pulmonary embolism. Sleep 2010;33:1069-74.
46. Cistulli PA, Phillips CL. Expanding the clinical spectrum of OSA - an association with pulmonary embolism? Sleep 2010;33:1009-10.
47. Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;2:3-9.
48. Scarabin PY, Aillaud MF, Amouyel P, et al. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarctiondthe PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Thromb Haemost 1998;80:749-56.
49. Tofler GH, Brezinski D, Schafer AI, et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 1987;316:1514-18.